Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus SODIUM IODIDE I 123.
GALLIUM GA 68 GOZETOTIDE vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on prostate cancer cells. After binding, the gallium-68 isotope emits positrons for PET imaging.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
148-222 MBq (4-6 mCi) intravenously as a single dose for PET imaging.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 1.5 hours (range 1.2–1.8 hours) based on decay of Gallium-68 and renal clearance. Clinically, this allows imaging up to 2–3 hours post-injection.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Renal excretion: 100% of administered dose eliminated unchanged in urine within 24 hours. No biliary or fecal elimination significant.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical